13.5  1.1 (8.87%)		12-05 16:00
Open: 12.42 High: 14.2 Volume: 534,928		Pre. Close: 12.4 Low: 12.1 Market Cap: 440(M)

Short term
Mid term
Targets	6-month :	16.63	1-year :	19.42
Resists	First :	14.23	Second :	16.63
Pivot price	12.23
Supports	First :	10.6	Second :	8.35
MAs	MA(5) :	12.32	MA(20) :	11.57
	MA(100) :	8.98	MA(250) :	0
MACD	MACD :	0.7	Signal :	0.7
%K %D	K(14,3) :	72.1	D(3) :	66.1
RSI	RSI(14): 67.2
52-week	High :	100.09	Low :	6.56

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ JBIO ] has closed above the upper band by 0.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 9.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	14.26 - 14.32	14.32 - 14.38
Low:	11.98 - 12.03	12.03 - 12.08
Close:	13.41 - 13.51	13.51 - 13.61

Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.

Sat, 06 Dec 2025
Jade Biosciences (NASDAQ:JBIO) Sees Large Volume Increase - Here's What Happened - MarketBeat

Thu, 04 Dec 2025
Does Jade Biosciences, Inc. (JBIO) Have the Potential to Rally 65% as Wall Street Analysts Expect? - Zacks Investment Research

Tue, 25 Nov 2025
Clear Street Initiates Coverage of Jade Biosciences (JBIO) with Buy Recommendation - Nasdaq

Tue, 18 Nov 2025
What Makes Jade Biosciences, Inc. (JBIO) a New Buy Stock - Nasdaq

Fri, 14 Nov 2025
Jade Biosciences Advances Autoimmune Therapies - TipRanks

Fri, 14 Nov 2025
Jade Biosciences, Inc. SEC 10-Q Report - TradingView

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	46 (M)
Shares Float	29 (M)
Held by Insiders	0.9 (%)
Held by Institutions	84.1 (%)
Shares Short	1,030 (K)
Shares Short P.Month	1,710 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	5.5
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-45 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	2.45
Price to Sales	0
Price to Cash Flow	-13.73

Dividend	2.4
Forward Dividend	0
Dividend Yield	17.7%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.